Highest-materiality recent filing
GeneDx Q2 revenue $114.4M, exome/genome volume up 32% YoY; reiterates FY guidance
Q2 revenue $114.4M (+11% YoY); exome/genome revenue $100.3M (+17% YoY).
Katherine Stueland elected Class II director: 18,325,894 for, 5,893,466 withheld, 3,409,327 broker non-votes.
GeneDx names Mark Gardner as President, effective June 15, 2026
Mr. Gardner, former Quest Diagnostics SVP, will oversee lab and commercial ops, reporting to CEO Katherine Stueland.
GeneDx Q1 revenue $102.3M (+17% YoY); exome/genome volume +34%; FY guidance $475-490M
Q1 revenue $102.3M (+17% YoY); exome/genome revenue $90.6M (+27% YoY).
GeneDx enters $100M term loan with Blackstone to repay existing credit facility
$100M term loan funded Feb 27, 2026; proceeds used to repay existing Perceptive Credit term loan.
GeneDx Q4 revenue $121M, +27% YoY; exome/genome +32%; reaffirms FY2026 guidance $540-555M
Q4 revenue $121M (+27% YoY); exome/genome revenue $104M (+32%, or +42% ex one-time).
GeneDx prelim FY2025 rev $427M (+41%); FY2026 guidance $540-555M
FY2025 exome/genome revenue ~$360M (+54% YoY); Q4 $104M (+32% YoY).
GeneDx Q3 2025 revenue $116.7M (+52% YoY), adjusted net income $14.7M; raises full-year guidance
Q3 revenue $116.7M (+52% YoY); exome/genome revenue $98.9M (+65% YoY).
GeneDx appoints Thomas Fuchs, SVP & Chief AI Officer at Lilly, as Class I director
Thomas Fuchs appointed to board effective September 17, 2025; board expands from 7 to 8 members.
GeneDx Q2 revenue $102.7M (+49% YoY); raises FY outlook to $400-415M
Exome/genome test revenue $85.9M (+69% YoY) on volume of 23,102 results (+28%).
GeneDx re-elects Casdin and Ruch as Class I directors; EY ratified as auditor
Eli D. Casdin re-elected with 16,013,641 votes for, 6,823,343 withheld.
GeneDx Q1 revenue $87.1M, exome/genome revenue up 62% YoY; raises FY 2025 guidance
Q1 exome/genome revenue $71.4M (+62% YoY); total revenue $87.1M (+42% YoY).
GeneDx to acquire Fabric Genomics for up to $51M; expands AI genomic interpretation globally
GeneDx will pay $33M cash at closing for Fabric Genomics; total consideration up to $51M based on milestone achievements (2025/2026 revenue and margin targets).
GeneDx Q4 revenue up 64% YoY to $95.3M; adjusted net income $16.8M; FY2025 guidance $350-360M
Q4 revenues $95.3M (+64% YoY); exome/genome revenue $78.8M (+101% YoY).
GeneDx reports prelim FY2024 revenue ≥$299M (+54% YoY), above prior guidance
Preliminary FY2024 revenue at least $299M (+54% YoY), above prior guidance of $284-290M.
GeneDx appoints Bryan Dechairo as COO with $450K salary and $2.7M RSU award
Bryan Dechairo appointed COO effective Jan 2, 2025; reports to CEO Katherine Stueland.
GeneDx achieves Q3 2024 profitability with $1.2M adjusted net income, raises FY guidance
Revenue $76.6M (+52% YoY); exome/genome revenue $60.0M (+77% YoY).
GeneDx Q2 revenue $68.9M (+52% YoY); raises FY24 revenue guidance to $255-265M
Exome/genome test revenue $50.7M (+77% YoY), volume 18,017 (+52% YoY).
GeneDx stockholders elect three Class III directors and ratify EY as auditor
Emily Leproust, Keith Meister, and Richard Pfenniger Jr. elected as Class III directors with over 17M votes for each.
GeneDx Q1 exome/genome revenue up 96% YoY; raises FY 2024 guidance to $235-245M
Revenue from continuing ops $61.5M (+51% YoY); exome/genome revenue $44.0M (+96% YoY).
GeneDx enters $75M at-the-market equity offering agreement with TD Securities
Company may sell up to $75M of Class A common stock through TD Cowen as agent.
GeneDx Q4 revenue $58.1M (+27% YoY); exome/genome revenue up 68%; guides FY2024 $220-230M
Q4 revenue from continuing ops $58.1M (+27% YoY); exome/genome revenue $39.2M (+68% YoY).
GeneDx prelim Q4 revenue >$57M, exome/genome rev +63% YoY; cash burn -51% YoY
Q4 continuing ops revenue >$57M (+24% YoY); exome/genome revenue >$38M (+63% YoY).
Continuing ops revenue $50.4M; exome and genome test revenue $34M (+42% YoY). Adjusted gross margin from cont ops 48%.
GeneDx Q2 2023: Exome/genome revenue up 36% YoY; cash burn down 36%
Continuing ops revenue $45.2M (+13% YoY); exome/genome rev. $28.7M (+36% YoY).
GeneDx adopts 2023 Equity Inducement Plan, reserves 500,000 shares for new hires
Board adopted 2023 Equity Inducement Plan on July 21, 2023, reserving 500,000 shares of Class A common stock.
GeneDx shareholders re-elect Stueland and Ryan as directors, ratify Ernst & Young
Katherine Stueland received 9,759,969 votes for and 2,895,500 withheld as Class II director.
GeneDx regains Nasdaq minimum bid price compliance after reverse stock split
Nasdaq notified GeneDx on May 18, 2023 that it met $1.00 minimum bid for 10 consecutive days.
Pro forma revenue from continuing ops $40.7M, up 7% YoY; whole exome/genome test revenue $22.4M, up 22%.
Reverse stock split at 1-for-33 ratio approved by Board on April 24, 2023; effective May 4, 2023.
GeneDx holders approve reverse split (1:10-1:50), new shares for $150M offering
Reverse stock split authorized at ratio 1:10 to 1:50, exact ratio set by board.
GeneDx amends Executive Chairman agreement: reduced time, base salary $337,500
Jason Ryan's employment as Executive Chairman extended to Dec 31, 2023.
GeneDx Q4 revenue $61.4M (+6.2% YoY), full-year net loss $667.6M; 2023 guidance reiterated
Combined revenue $61.4M in Q4 (+6.2% YoY); full year $234.7M (+10% YoY). Net operating loss $667.6M for FY22.
GeneDx director Dr. Michael Pellini resigns; Section 32 remains supporter after $150M financing
Dr. Michael Pellini stepped down from the Board effective February 14, 2023.
GeneDx raises ~$150M via equity offering at $0.35/share; Corvex affiliates invest $35M
Offering of 428.6M shares at $0.35 per share; net proceeds estimated at ~$143M.
Investor presentation furnished as Exhibit 99.1 for the 41st Annual J.P. Morgan Healthcare Conference on January 12, 2023.
GeneDx (formerly Sema4) eyes 37-40% revenue growth to ~$170-173M in 2022; guides 2023 rev $205-220M
Preliminary pro forma 2022 revenue $170-173M, up 37-40% YoY from $123.7M.
Sema4 receives Nasdaq delisting notice and settles $42M payor dispute
Nasdaq notified Sema4 that its stock bid price below $1.00 for 30 consecutive days; has 180 days to regain compliance by June 26, 2023.
Exits reproductive/women's health testing; will close Stamford lab by Q1 2023, eliminate ~500 positions (32.5% of workforce).
Sema4 names Kevin Feeley CFO as interim CFO Richard Miao departs
Interim CFO Richard Miao leaves Sept 2, 2022; entitled to accrued compensation.
Q2 total revenue $36.2M (or $66.3M excluding $30.1M prior-period adjustments); net loss $85.7M; adjusted net loss $72.9M.
Sema4 CAO Shawn Assad to resign; Richard Miao appointed Principal Accounting Officer
Shawn Assad resigns as Chief Accounting Officer effective August 30, 2022; departure not related to accounting disagreements.
Sema4 CFO Isaac Ro to depart Aug. 9, 2022; Richard Miao named interim CFO
CFO Isaac Ro to leave Aug. 9, 2022; entitled to 9 months salary continuation and 12 months COBRA.
Total revenue $53.9M (incl. COVID-19); ex-COVID revenue $50.1M, up 4% YoY.
Sema4 closes GeneDx acquisition; Stueland becomes CEO, Schadt shifts to President
Acquired GeneDx for $150M cash + 80M shares upfront; up to $150M in revenue-based milestones.
Sema4 shareholders approve GeneDx acquisition, authorize share increase to 1B
Stockholders approved shares for GeneDx acquisition: 178,157,301 for, 104,365 against.
Sema4 announces non-reliance on previously issued financial statements and reports Q4 2021 results
Non-reliance on previously issued financial statements for years ended Dec 31, 2020 and 2019 due to expense classification errors in cost of services and selling & marketing.
Q4 2021 revenue $57.8M (up 24% ex-COVID); full-year revenue $212.2M. Net loss $40.2M Q4, $245.4M full year.
Sema4 President and COO James Coffin departs; gets $550K severance, bonus, option acceleration
James Coffin, President and COO, leaves for personal reasons effective Feb 1, 2022.
Sema4 agrees to acquire GeneDx from OPKO for $150M cash + 80M shares; $200M PIPE at $4.00/share
Total consideration: $150M cash + 80M Sema4 shares + up to $150M in revenue-based milestones.
Following Mr. Gardner’s appointment, Bryan Dechairo will transition into a role focused on leading the Company’s product, technology and innovation initiatives.
On June 16, 2026, GeneDx Holdings Corp. (the “Company”) announced the appointment of Mark Gardner, age 60, in the role of President, which was effective on June 15, 2026.
On January 2, 2025, GeneDx Holdings Corp. (the “Company”) announced the appointment of Bryan Dechairo, Ph.D., age 52, in the newly created role of Chief Operating Officer, effective immediately.
On April 24, 2023, Rachel Sherman and Dennis Charney notified the Board that they will not stand for re-election as directors of the Company at the Company’s 2023 annual meeting of stockholders
On April 24, 2023, Rachel Sherman and Dennis Charney notified the Board that they will not stand for re-election as directors of the Company at the Company’s 2023 annual meeting of stockholders
On February 14, 2023, Dr. Michael Pellini notified GeneDx Holdings Corp. (“GeneDx”) that he is stepping down from the Board of Directors (the “Board”), effective immediately
On August 25, 2022, Kevin Feeley, the Company’s current Senior Vice President of Operations and Head of GeneDx, was appointed to also serve as the Chief Financial Officer, effective August 25, 2022.
On August 26, 2022, Sema4 Holdings Corp. (“Sema4 Holdings” or the “Company”) announced that its Interim Chief Financial Officer and Deputy Chief Financial Officer, Richard Miao, will leave the Company.
Effective upon Mr. Assad’s departure, Richard Miao will serve as the Company’s Principal Accounting Officer.
On June 27, 2022, Shawn Assad notified Sema4 Holdings Corp. (the “Company”) that he will resign from his role as Chief Accounting Officer of the Company, effective August 30, 2022.
its Chief Financial Officer, Isaac Ro, will leave the Company to pursue other career opportunities.
Richard Miao, the Company’s current Senior Vice President of Financial Planning & Analysis and Treasurer, was promoted to Deputy Chief Financial Officer and appointed to serve as the Interim Chief Financial Officer, effective June 13, 2022.
Max materiality 0.95 · Median 0.75 · Most common event earnings